SGLT-2 Inhibitors in Development for Type 2 Diabetes Treatment

Mithun Bhartia¹, Abd A. Tahrani²,³, and Anthony H. Barnett³,⁴

¹Heart of England NHS Foundation Trust, Good Hope Hospital, Sutton Coldfield, Birmingham, B75 7RR, UK. ²Heart of England NHS Foundation Trust, Birmingham Heartlands Hospital, Bordesley Green East, Birmingham, B9 5SS, UK. ³University of Birmingham, Birmingham, UK. ⁴BioMedical Research Centre, Heart of England NHS Foundation Trust, Birmingham Heartlands Hospital, Bordesley Green East, Birmingham, B9 5SS, UK. Address correspondence to Anthony H. Barnett, e-mail: anthony.barnett@heartofengland.nhs.uk

Abstract

The prevalence of type 2 diabetes is increasing worldwide. The majority of currently available glucose-lowering agents work via insulin-dependent mechanisms and have significant limitations. Hence, there is a need for newer treatments utilizing novel therapeutic targets. Drugs which inhibit the sodium glucose cotransporter in the renal tubules (SGLT-2 inhibitors), represent a novel class of drugs under development. By inhibiting SGLT-2, they promote increased renal glucose excretion and thereby calorie loss with improved glycemic control and weight loss. Dapagliflozin is most advanced in development of this new drug class and currently undergoing phase 3 trials. In addition to its glucose lowering effect, dapagliflozin appears to have favorable impacts on weight and blood pressure, with low risk of hypoglycemia. However, as with all new treatments, long-term safety is an issue. Clinical trials showed increased risk of genital and possibly urinary infections with dapagliflozin. Furthermore, concerns have arisen regarding a possible increased incidence of breast and bladder cancer in patients on dapagliflozin. However, it needs further investigation to confirm or refute whether these concerns are concrete.

Keywords: glucose reabsorption • kidney • renal glucose • SGLT • sodium glucose cotransporter • type 2 diabetes

Introduction

The prevalence of diabetes in the United Kingdom (UK) is 4.26% (Diabetes UK, Oct 2010), with a diagnosed population of 2.8 million people and accounting for 10% of the total National Health Service spend [1]. Add to this figure an estimated half a million undiagnosed and that by 2025 it is estimated that over 4 million people will have the condition [1] At any one time, between 1 in 5 and 1 in 10 people in hospital has diabetes. This is associated with poorer outcomes and prolonged admissions. Worldwide more than 300 million people have diabetes, the great majority (around 90%) with type 2 diabetes (T2D) [2], and it is anticipated that the figure will reach 438 million by 2030 [3]. T2D is progressive disorder in which the pancreatic beta-cells secrete increasing amounts of insulin to compensate for insulin resistance. Progressive beta-cell failure results in insufficient insulin production which is unable to overcome insulin resistance, leading to glucose intolerance and eventually T2D [4, 5]. Factors affecting insulin resistance include genetic predisposition, age, lack of physical activity, diet, and obesity. T2D is associated with serious micro- and macrovascular complications which contribute significantly to mortality and morbidity [6]. About 50% of patients show signs of complications at the
time of diagnosis. In addition to the management of cardiovascular risk factors (such as hypertension and dyslipidemia), intensive glycemic control has been shown to prevent the development and slow the progression of microvascular complications. Cardiovascular outcomes and mortality may also be improved if such management is begun early in the course of T2D [7]. Hence, good glycemic control (particularly in the early stages of T2D) is a highly important aspect in the management of these patients to reduce the morbidity associated with this condition.

There are several drug classes which improve glycemic control, including biguanides, thiazolidinediones (TZD), sulfonylureas (SU), and alpha-glucosidase inhibitors. All are initially effective, but they fail to maintain normoglycemia as monotherapy in the long term (because of the progressive nature of beta-cell dysfunction), resulting in the requirement for combination therapy and insulin. These agents may be associated with significant side effects including hypoglycemia (SU, insulin), weight gain (SU, TZD, and insulin), edema (TZD), and possibly adverse cardiovascular outcomes (TZD). There is also a safety requirement for glucose self-monitoring (SU, insulin) for some drugs, and the need to use injections (insulin). Finally, none of these agents has been shown to alter the natural history of the disease.

Hence, there is a need for treatments that bring about sustained improvement in glycemic control, slow/reverse the decline in beta-cell function, are weight neutral or cause weight loss, do not cause hypoglycemia, and have no deleterious effects on cardiovascular outcomes. New classes of drugs were introduced around 6 years ago based on their effects on the incretin hormone axis. Incretin-based therapies are either weight neutral (DPP-4 inhibitors) or cause weight loss (GLP-1 analogues), and involve no increased risk of hypoglycemia compared with placebo (unless combined with SU). These newer agents have also shown increased beta-cell survival in animal studies. The drugs work primarily by effects on insulin secretion or insulin sensitivity in the liver, muscle, adipose tissue or by decreasing glucose absorption from the gut.

Another important organ involved in glucose handling is the kidney. Another class of glucose-lowering drugs, which works by effects on the kidney, is currently under development, the sodium glucose cotransporter 2 (SGLT-2) inhibitors. In this article, we will review the available data on these agents.

**Renal glucose handling**

During the post-absorptive state, the kidney both consumes and releases glucose. Renal glucose release and uptake are under hormonal control. The kidney can compensate, at least partially, for impaired hepatic glucose production, and contributes to the excessive glucose release seen in both patients with types 1 and 2 diabetes.

In normal individuals, approximately 180 g of glucose is filtered by the kidneys [8, 9]. Virtually, all the glucose filtered through the glomeruli is reabsorbed by the proximal renal tubule mediated by SGLT-1 and -2, which are located in the tubule. Because of the presence of the SGLT receptors, no glucose appears in the urine under optimal conditions. During periods of hyperglycemia, the glucose reabsorptive capacity of the kidney increases in proportion to the plasma glucose concentration. It is only when the plasma glucose load is high enough to saturate these transporters (despite their overexpression) that glucose appears in the urine [9].

SGLT-2 is a low-affinity high-capacity transporter, and is present in the S1 segment of the proximal tubule. It accounts for 90 percent of the glucose reabsorbed by the proximal renal tubule mediated by SGLT-1 and -2, which are located in the tubule. Because of the presence of the SGLT receptors, no glucose appears in the urine under optimal conditions. During periods of hyperglycemia, the glucose reabsorptive capacity of the kidney increases in proportion to the plasma glucose concentration. It is only when the plasma glucose load is high enough to saturate these transporters (despite their overexpression) that glucose appears in the urine [9].

SGLT-2 is a low-affinity high-capacity transporter, and is present in the S1 segment of the proximal tubule. It accounts for 90 percent of the glucose reabsorbed by the kidneys. SGLT-1 is a high-affinity low-capacity transporter located on the S3 (distal) segment of the proximal tubule. It accounts for 10 percent of the glucose reabsorbed from the kidneys. SGLT-2 is also present abundantly in the intestine and plays an important role in glucose absorption from that site.

**Concept of SGLT-2 inhibition**

There are rare inherited conditions where there is dysfunction of the SGLT-1 and SGLT-2 trans-
horers [10]. Individuals with the SGLT-1 mutation develop glucose-galactose malabsorption. This causes profuse diarrhea which is reversible on controlling glucose and lactose in the diet. These people have only mild glycosuria. Severe diarrhea has limited the utilization of SGLT-1 as a therapeutic target for glucose-lowering treatment. Similarly, the SCL5A2 gene mutation causes dysfunction of the SGLT-2 transporter. Glucose reabsorption is severely impaired, and there is heavy glycosuria. Despite this, the person remains well, and there appear to be no other complications.

Several decades ago, there was interest in a substance called phlorizin isolated from the bark of apple trees. It is a non-specific inhibitor of both SGLT-1 and SGLT-2 transporters, and the results of animal studies were encouraging. Unfortunately, it was poorly absorbed from the intestine and caused additional inhibition of SGLT-1 transporters in the intestine and serious side effects. Hence, the drug was never pursued in humans.

However, given the experience from gene mutations and the potential for SGLT-2 inhibition, a new class of drugs has been developed which inhibit SGLT-2; several of which are now in phase 3 trials. There are various SGLT-2 inhibitors in development (e.g. canagliflozin, sergilofzin, re-mogflozin). The most advanced drug in clinical trials is dapagliflozin, a medication being co-developed by Astra Zeneca and Bristol-Myers Squibb. In this article, we will mainly consider the effects of dapagliflozin.

**Preclinical studies**


**Pharmacokinetics and pharmacodynamics**

Single and multiple ascending dose (SAD and MAD) studies with dapagliflozin in healthy people and those with T2D confirmed a pharmacokinetic profile consistent with once-daily dosing [12, 13]. The half-life is around 17 hours with dose-dependent concentrations. There is rapid absorption of the drug with T_max of around 1-2 hours. There is minimal renal excretion of the drug as it is protein-bound.

There was a dose-dependent increase in glycosuria in T2D patients and healthy persons reaching a plateau at 20 mg/day. Dapagliflozin can be co-administered with pioglitazone, metformin, glimepiride, or sitagliptin without dose adjustment of either drug [14]. It can also be administered without regard to meal times [15]. The in vivo success led to clinical evaluation in people with diabetes and healthy subjects.

**Clinical studies**

In a prospective, 12-week, randomized, parallel-group, double-blind, placebo-controlled study on drug-naive T2D patients with HbA1c 7-10%, patients were assigned dapagliflozin (2.5-50 mg), metformin, or placebo. Changes in FPG were dose-related, but there was no dose-related response to postprandial glucose or HbA1c. Even the lowest dose of dapagliflozin produced a near-maximal effect on postprandial glucose [16].

A double-blind triple-arm 12-week randomized controlled trial was performed in patients receiving oral antidiabetes drugs alongside insulin [17]. Basal insulin dose was ≥50 units and stable for ≥6 weeks. Therapies included metformin ≥1,000 mg and/or pioglitazone ≥30 mg, or rosiglitazone 4 mg for ≥6 weeks and insulin therapy for ≥12 weeks. Patients were randomly assigned to placebo, 10 mg dapagliflozin, or 20 mg dapagliflozin in addition to their oral antidiabetes agents, with a 50% reduction to their daily insulin dose. One event of renal failure occurred during treatment with 10 mg dapagliflozin. The patient was on multiple antihypertensive agents (enalapril, carvedilol and furosemide). Furosemide and enalapril therapy were withheld, and the renal failure resolved with oral rehydration.

The largest phase 3, multi-center, double-blind, parallel-group, placebo-controlled trial involved 546 adults with T2D [18]. They were receiving daily metformin (≥1500 mg per day), and were randomly assigned to add on placebo or dapagliflozin (2.5 mg, 5 mg, or 10 mg). The primary endpoint of the trial was a change in HbA1c after week 24. The secondary endpoints were changes in fasting glucose and change in body weight. There was a dose-dependent reduction in HbA1c with a reduction of 0.84% in patients with 10 mg compared with 0.3% in the placebo group. Fasting glucose was also reduced in the dapagliflozin group (-2.66%, -3.66%, and -3.43% for 2.5, 5, and 10 mg, respectively) compared with -1.02% for placebo.
All patients on dapagliflozin had a greater weight loss compared with placebo. Patients on 10 mg had a change in baseline of -2.9 kg compared with placebo (-0.9 kg). Also, around 25% of all patients in the dapagliflozin group lost at least 5% of their initial baseline body weight. There was no significant increase in urine infection compared with placebo.

Another trial involved patients who were poorly controlled on insulin alone [19]. Patients were randomized to receive 2.5, 5, 10 mg dapagliflozin or placebo for 48 weeks. Baseline HbA1c was 8.5% with a weight of 85 kg. The dapagliflozin group had a higher rate of urinary tract infections (7.9-10.8%) compared with placebo (5.1%) [19, 20].

In another randomized controlled trial of inadequately controlled patients with T2D, the baseline treatment was metformin which was titrated to control fasting glucose. 406 patients received up to 10 mg/day of dapagliflozin compared with 408 who received up to 20 mg of glipizide based on glycemic response and tolerability. By one year of follow up, there was a decrease in HbA1c of -0.52% in both groups. Patients in the dapagliflozin group lost 3.2 kg weight compared with the sulfonylurea group which gained 1.4 kg. The dapagliflozin group had better improvements in blood pressure and HDL cholesterol (p < 0.0001). The dapagliflozin group also had less hypoglycemia compared with the glipizide group (3.5% vs. 40.8%), and there were fewer serious adverse events (6.6% vs. 11.1%). Patients had more urinary tract infections with dapagliflozin (10.8% vs. 6.4%) and more genital infections (12.3% vs. 2.7%) [21]. These side effects were more common in women.

New data were presented as a late breaking poster at the ADA this year [22]. This was an extension of the above-mentioned original study to assess long term efficacy and safety. The 2-year results showed a reduction of baseline HbA1c with dapagliflozin of -0.32% vs. -0.14% with glipizide. Dapagliflozin produced a sustained reduction in body weight of -3.7 kg vs. a +1.36 kg increase for.

### Table 1. Results of trials with dapagliflozin as add-on therapy in diabetic patients with different baseline characteristics

<table>
<thead>
<tr>
<th>Organ</th>
<th>HbA1c change (%)</th>
<th>Weight change (kg)</th>
<th>Hypoglycemia</th>
<th>UTI</th>
<th>Genital infections</th>
</tr>
</thead>
<tbody>
<tr>
<td>List et al., baseline characteristics: drug naive (trial for 12 weeks) [16]</td>
<td>Add-on dapagliflozin 2.5-50 mg</td>
<td>-0.55-0.9</td>
<td>-2.5 to -3.4</td>
<td>6-10%</td>
<td>5% to 12%</td>
</tr>
<tr>
<td></td>
<td>Add-on metformin</td>
<td>0.0</td>
<td>-1.7</td>
<td>9%</td>
<td>9%</td>
</tr>
<tr>
<td>Add-on placebo</td>
<td>0.0</td>
<td>-1.2</td>
<td>4%</td>
<td>6%</td>
<td>0%</td>
</tr>
<tr>
<td>Wilding et al., baseline characteristics: OH agents + 50% insulin (trial for 12 weeks) [17]</td>
<td>Add-on dapagliflozin 10 mg</td>
<td>-0.61</td>
<td>-4.5</td>
<td>29%</td>
<td>0%</td>
</tr>
<tr>
<td></td>
<td>Add-on dapagliflozin 20 mg</td>
<td>-0.69</td>
<td>-4.3</td>
<td>25%</td>
<td>7%</td>
</tr>
<tr>
<td></td>
<td>Add-on placebo</td>
<td>-0.09</td>
<td>-1.9</td>
<td>13%</td>
<td>0%</td>
</tr>
<tr>
<td>Bailey et al., baseline characteristics: metformin (trial for 52 weeks) [18]</td>
<td>Add-on dapagliflozin 2.5 mg</td>
<td>-0.67</td>
<td>-2.2</td>
<td>2%</td>
<td>3%</td>
</tr>
<tr>
<td></td>
<td>Add-on dapagliflozin 5 mg</td>
<td>-0.70</td>
<td>-3.0</td>
<td>4%</td>
<td>7%</td>
</tr>
<tr>
<td></td>
<td>Add-on dapagliflozin 10 mg</td>
<td>-0.84</td>
<td>-2.9</td>
<td>4%</td>
<td>7%</td>
</tr>
<tr>
<td></td>
<td>Add-on placebo</td>
<td>-0.30</td>
<td>-0.9</td>
<td>3%</td>
<td>5%</td>
</tr>
<tr>
<td>Nauck et al., baseline characteristic: metformin background (trial for 52 weeks) [21]</td>
<td>Add-on dapagliflozin</td>
<td>0.5</td>
<td>-3.2</td>
<td>3.5%</td>
<td>11.0%</td>
</tr>
<tr>
<td></td>
<td>Add-on glipizide</td>
<td>0.5</td>
<td>1.4</td>
<td>41.0%</td>
<td>6.4%</td>
</tr>
<tr>
<td>Ferannini et al., baseline characteristics: drug naive (trial for 24 weeks) [23]</td>
<td>Add-on dapagliflozin 2.5 mg</td>
<td>-0.58</td>
<td>-3.3</td>
<td>1.5%</td>
<td>4.6%</td>
</tr>
<tr>
<td></td>
<td>Add-on dapagliflozin 5 mg</td>
<td>-0.77</td>
<td>-2.8</td>
<td>0%</td>
<td>12.0%</td>
</tr>
<tr>
<td></td>
<td>Add-on dapagliflozin 10 mg</td>
<td>-0.89</td>
<td>-3.2</td>
<td>2.9%</td>
<td>5.7%</td>
</tr>
<tr>
<td></td>
<td>Add-on placebo</td>
<td>-0.23</td>
<td>-2.2</td>
<td>2.7%</td>
<td>4.0%</td>
</tr>
<tr>
<td>Strojek et al., baseline characteristics: glimepiride background (trial for 24 weeks) [24]</td>
<td>Add-on dapagliflozin 2.5 mg</td>
<td>-0.58</td>
<td>-1.18</td>
<td>7.1%</td>
<td>3.9%</td>
</tr>
<tr>
<td></td>
<td>Add-on dapagliflozin 5 mg</td>
<td>-0.63</td>
<td>-1.56</td>
<td>6.9%</td>
<td>6.9%</td>
</tr>
<tr>
<td></td>
<td>Add-on dapagliflozin 10 mg</td>
<td>-0.82</td>
<td>-2.26</td>
<td>7.9%</td>
<td>5.3%</td>
</tr>
<tr>
<td></td>
<td>Add-on placebo</td>
<td>-0.13</td>
<td>-0.72</td>
<td>4.8%</td>
<td>6.2%</td>
</tr>
</tbody>
</table>

**Legend:** OH: oral hypoglycemic. UTI: urinary tract infections.
glipizide. There was a lower risk for hypoglycemia in the dapagliflozin group (4.2%) as compared to glipizide (45.8%). The overall rate of adverse events was similar after 2 years. Urinary tract infections (UTIs) were 13.5% for dapagliflozin group as compared to 9.1% for glipizide. Genital infections were 14.8% for dapagliflozin group (8% men, 23.3% women) as compared to 2.9% for glipizide (0.4% men, 5.9% women). The majority of events was mild to moderate and responded to standard care. These occurred predominantly in the first year. There was 1 discontinuation in each arm owing to UTI and 3 discontinuations in the dapagliflozin arm because of genital infections occurring in year 1 with none occurring in year 2.

In a 24-week, randomized, parallel-group, double-blind, placebo-controlled phase 3 trial, patients with HbA1c 7.0-10% were assigned to receive once-daily 2.5, 5, or 10 mg dapagliflozin, or placebo [23]. This was given once daily either in the morning (main cohort) or evening (exploratory cohort) for 24 weeks. Patients with HbA1c 10.1-12% (high exploratory cohort) were randomized to receive a morning dose of 5 or 10 mg/day dapagliflozin.

Another 24-week, randomized, placebo-controlled, double-blind trial was conducted on patients with HbA1c 7-10% on glimepiride 4 mg/day for 24 weeks. Patients were assigned to placebo or dapagliflozin (2.5, 5, or 10 mg/day). The primary endpoint was change of HbA1c from baseline. Secondary endpoints were change in body weight and other glycemic parameters. Patients on dapagliflozin had significantly improved HbA1c and reduced weight as compared to placebo (Table 1) [24].

Safety and place in therapy

Most guidelines on management of T2D recommend initial pharmacotherapy with metformin, and then adding in a sulfonylurea, if the agreed target HbA1c is not achieved. This may be followed by addition of pioglitazone or a DPP-4 inhibitor or insulin (although there is also a place for DPP-4 inhibitors in the second line under certain circumstances). Insulin is commonly used as monotherapy or in combination with oral agents, especially metformin if the desired outcome with oral drugs alone is not achieved. GLP-1 agonists are also gaining popularity, particularly where avoidance of weight gain is a significant issue which makes the use of insulin difficult or unacceptable.

Whilst there is still much work to do, the SGLT-2 inhibitors represent a new class of oral antidiabetes agents which appear to have equivalent efficacy to other oral agents, but with the added benefit of weight loss, blood pressure reduction, and low risk of hypoglycemia. The mode of action is insulin-independent which potentially makes them an option at any stage in the disease process and in any combination. In this respect, they could pose a significant threat to the primacy of the sulfonylureas as second-line therapy, and may compete second and third line with other oral agents or even the GLP-1 agonists. The latter may have greater efficacy, but many patients will prefer to try an oral agent before an injectable. Also, SGLT-2 inhibitors are likely to be significantly cheaper with the added benefit of weight loss which appears equivalent to that achieved with GLP-1 agonists.

On the downside, there remain significant questions which will initially limit the use of these agents. These include a lack of durability and safety issues relating to use in renal impairment and the hypothetical possibility of significant side effects in the elderly during acute illness complicated by dehydration. Also, the mechanism of blood pressure-lowering is poorly understood, and, whilst likely to be of long-term benefit, much more work needs to be done in this area, including the potential for interactions with established antihypertensive agents. Issues surrounding increased risk of genital infection (how severe?, how easy to treat?, recurrence rates?) and possibly urinary tract infection also need clarifying.

In the trials, 5 patients on dapagliflozin were reported to have elevation of transaminases by 3 times the upper limit of normal, with accompanying total bilirubin more than twice the upper limit of normal. There was an adequate explanation for these results in all but one case [26]. In the case in question, there was a “probable diagnosis of mild to moderately severe dapagliflozin-induced liver injury”.

Overall, there was similarity between the dapagliflozin group (1.4%) vs. control group (1.3%) in the proportion of patients reporting cancers and unspecified tumors [25]. However, there was an imbalance in the number of breast cancer and bladder cancer cases. There were 9 cases of breast cancer in the dapagliflozin group (2223 patients) as compared to 1 case in placebo (1053 patients). All these cases were diagnosed within the first year of the study [25, 26]. However, these figures were higher than the predicted number of 7.1
cases based on the Surveillance Epidemiology and End Results (SEER) program to calculate the expected number of breast cancer cases in a reference US population. It remains uncertain whether the use of dapagliflozin is associated with increased risk of breast cancer. Further studies are needed.

Bladder cancers were reported in 9 out of 5478 patients treated with dapagliflozin compared with 1 case in 3156 patients in the control group [25, 26]. All were men and 5 of the 10 cases were diagnosed within the first year. Six patients had hematuria at the start of the study and before receiving the study drug. Based on the SEER data, only 2 cases were expected in the male dapagliflozin group and one in the male control group. In the female cohort, one would have expected to find 0.5 cases in the dapagliflozin group compared to 0.22 in the control group. The use of an external data source (SEER) as reference population has limitations including the fact that there could be a detection bias because of more frequent urine examinations. In preclinical studies of dapagliflozin in rodents (using 100-fold doses over the maximum recommended dose in humans) over 2 years, there was no evidence of carcinogenicity [25].

Conclusions

SGLT-2-inhibitor drugs appear to be a promising new development for the management of T2D. They could be useful both as monotherapy and in any combination with other antidiabetes agents, including insulin. The novel properties of this drug class are especially welcome at a time when tolerability issues and side effects of several commonly used antidiabetes agents impede their use to maximal potential.

However the incidence of the bladder and breast cancer cases and elevation of hepatic enzymes pose significant safety questions. These were considered by the advisory committee to the FDA recently (July 2011). The voting was 9 to 6 recommending non-approval of the drug because of these safety concerns.

The FDA hopes to make a final decision by end of October 2011, but if the drug is licensed, it is expected that this will be dependent on an agreement with the manufacturers to do large long-term safety studies. Whether these concerns will affect other SGLT-2 inhibitors in development remains to be seen.

Disclosures: MB is a clinical fellow at Good Hope Hospital. The views expressed in this report are those of the author(s) and not necessarily those of the National Health Service, Good Hope Hospital, or the Department of Health. AAT is a research training fellow supported by the National Institute for Health Research. The views expressed in this report are those of the author(s) and not necessarily those of the National Health Service, National Institute for Health Research, or the Department of Health. AAT has also won research grants from Sanofi-Aventis and Novo Nordisk UK Research Foundation. AHB has received honoraria for lectures and advisory work from BMS/Astra-Zeneca, Takeda, MSD, Novartis, Boehringer Ingelheim, Sanofi-Aventis, Eli Lilly, Novo Nordisk, and Roche.

References
4. Weyer C, Tataranni PA, Bogardus C, Pratley RE. Insulin resistance and insulin secretory dysfunction are independent predictors of worsening of glucose tolerance during each stage of development Diabetes Care 2001; 24:89-94.
12. Komoroski B, Vachharajani N, Boulton D, Kornhauser D, Gerales M, Li L, Pfister M. Dapagliflozin, a novel SGLT2 inhibitor, induces dose-dependent glucosuria...


